We are happy to present our work at the San Antonio Breast Cancer Symposium , December 7-10
Workshop: Clinical Research: From Study Design to Scientific Presentation
Date: 7.12.2021; Time: 11:00 am – 1:00 pm CT.
Moderator: Aditya Bardia, MD, MPH
Presenter: Nekljudova V.
Date: 8.12.2021; Time: 7:00 am – 8:30 am CT. Spotlight Poster Discussion 2: Insights to CDK4/6i resistance
PD2-04 Poster discussion: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib
Denkert C, Marmé F, Martin M, et al.
Date: 8.12.2021; Time: 5:00 pm – 6:30 pm CT. Ongoing Trials Poster Session 1: Adjuvant radio- and chemotherapy timing - concurrent or sequential?
OT1-02-01TIP Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA
Marmé F, Schmidt M, Furlanetto J, et al.
Date: 9.12.2021; Time: 7:00 am – 8:30 am CT. Spotlight Poster Discussion 9: Evaluating Emerging and Established Biomarkers
PD9-07 Poster discussion: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer
Wege AK, Vladimirova V, Solbach C, et al.
Date: 9.12.2021; Time: 5:00 pm – 6:30 pm CT. Prognostic and Predictive Factors - Prognostic Factors: Clinical Testing and Validation
P4-04-14 Poster: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study
Galas K, Gleitsmann M, Rey J, et al.
Date: 10.12.2021; Time: 9:15 am CT. GENERAL SESSION 4 - Hall 3
GS4-03: Oral presentation Patient-reported outcomes (PROs) for the intergroup sentinel mamma study (INSEMA, GBG75, ABCSG43): Persistent impact of axillary surgery on arm and breast symptoms in early breast cancer
Gerber B, Stachs A, Veselinovic K et al.
Date: 10.12.2021; Time: 7:00 am – 8:30 am CT. Prognostic and Predictive Factors: Predictive Biomarkers for Targeted Therapies
P5-13-36 Poster: Germline BRCA1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study
Loibl S, Hauke J, Gelmon K, et al.
Date: 8.12.2021; Time: 9:45 am CT, GENERAL SESSION 2 - Hall 3
Discussant: Anne Blaes, MD
University of Minnesota, Minneapolis, MN
GS2-05 Oral presentation: Randomized comparison of adjuvant aromatase inhibitor exemestane + ovarian function suppression (OFS) vs tamoxifen + OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer: update of the TEXT and SOFT trials
Regan MM, Walley BA, Fleming GF, et.al
Date: 8.12.2021; Time: 7:00 am – 8:30 am CT
Spotlight Poster Discussion 2: Insights to CDK4/6i resistance
PD2-09 Poster discussion: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Gnant M, Dueck AC, Frantal S, et al.
Date: 8.12.2021; Time: 5:00 pm – 6:30 pm CT
Ongoing Trials Poster Session 1: Antibody-drug Conjugates
OT1-02-03 TIP Poster: Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)
Geyer, Jr CE, Untch M, Prat , et al.
Date: 9.12.2021; Time: 5:00 pm – 6:30 pm CT
Psychosocial, QOL, and Educational Aspects: QOL - Supportive Care
P4-10-01 Poster: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)
Naughton MJ, Zahrieh D, Gnant M, et al.
Date: 10.12.2021; Time: 7:00 am – 8:30 am CT
Treatment: Therapeutic Strategies - New Drugs and Treatment Strategies
P5-16-01 Poster: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple‑negative breast cancer (mTNBC)
Loibl S, Tolaney SM, Punie K, et al.
Date: 10.12.2021; Time: 10:45 am CT, GENERAL SESSION 4 - Hall 3
GS4-09 Oral presentation: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
Ganz PA, Bandos H, Spanic T, et al.